Kymera Therapeutics, Inc. (KYMR) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kymera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$48.6 M, a 18.6% decline year-over-year.
  • Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$155 M, a 2.81% increase year-over-year.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$147 M, a 5.07% increase from 2022.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$155 M, a 54.5% decline from 2021.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$100 M, a 120% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$155 M -$48.6 M -$7.63 M -18.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$147 M -$14.4 M +$20.5 M +58.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$167 M -$52.9 M -$9.87 M -22.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$158 M -$38.8 M +$1.46 M +3.62% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$159 M -$40.9 M -$4.24 M -11.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$155 M -$34.9 M -$965 K -2.85% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$154 M -$43 M -$14.4 M -50.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$139 M -$40.3 M -$15.6 M -63.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$124 M -$36.7 M -$23.6 M -181% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$100 M -$33.9 M -$21.2 M -167% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$79 M -$28.6 M -$20.6 M -258% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$58.4 M -$24.7 M -$10.7 M -76.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$47.7 M -$13.1 M -$2.14 M -19.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$45.6 M -$12.7 M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$7.99 M +$3.43 M +30.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$14 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$10.9 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q3 2019 -$11.4 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.